Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announces the presentation of interim results from the CONVERT Study at the 20
Phase III clinical trial of [18F]flurpiridaz PET diagnostic radiopharmaceutical meets co-primary endpoints for detecting Coronary Artery Disease (CAD) Trial also met its first key secondary endpoint,
Late in 2021, Aerogen® (Galway, Ireland) and CanSinoBIO (SSE: 688185, HKEX: 06185) (Tianjin, China) announced a development and commercial supply partnership for the inhaled delivery of CanSinoBIO’s R
Graminex®, L.L.C. is pleased to announce it has completed a clinical study with Graminex® Flower Pollen Extract for women’s urinary incontinence and urinary health with positive results. This study wa
PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), today announced the opening of its Clinical Services Center of Excellence in Bridgewater, MA, th
/newsonfloor/media/post_banners/j1VV4v3EapChqBhygTeb.jpg)
/newsonfloor/media/post_banners/Ol65di7kISXaYbcWr4CT.jpeg)
![GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease](https://img-cdn.thepublive.com/fit-in/560x320/filters:format(webp)/newsonfloor/media/post_banners/OprjOgfJAobSFYs7l8S8.jpg)
/newsonfloor/media/post_banners/3eDyWanNKchpQ1EdGcp5.jpg)
/newsonfloor/media/post_banners/d9FxamWk0BtNUBDlwURy.jpeg)
/newsonfloor/media/post_banners/feyb6dpK6T9DBaETAE4s.jpg)
